Cognitive Performance Trajectories Before and After Sleep Treatment Initiation in Middle-Aged and Older Adults: Results from the Health and Retirement Study

Author(s):  
Christopher N Kaufmann ◽  
Mark W Bondi ◽  
Wesley K Thompson ◽  
Adam P Spira ◽  
Sonia Ancoli-Israel ◽  
...  

Abstract BACKGROUND Sleep disturbances are associated with risk of cognitive decline but it is not clear if treating disturbed sleep mitigates decline. We examined differences in cognitive trajectories before and after sleep treatment initiation. METHODS Data came from the 2006-2014 Health and Retirement Study. At each of five waves, participants were administered cognitive assessments and scores were summed. Participants also reported if, in prior two weeks, they had taken medications or used other treatments to improve sleep. Our sample (N=3,957) included individuals who at HRS 2006 were >50 years, had no cognitive impairment, reported no sleep treatment, and indicated experiencing sleep disturbance. We identified differences between those receiving vs. not receiving treatment in subsequent waves, and among those treated (N=1,247), compared cognitive trajectories before and after treatment. RESULTS At baseline, those reporting sleep treatment at subsequent waves were more likely to be younger, female, Caucasian, to have more health conditions, to have higher BMI, and more depressive symptoms (all p’s≤0.015). Decline in cognitive performance was mitigated in periods after sleep treatment vs. periods before (B=-0.20, 95% CI=-0.25, -0.15, p<0.001; vs., B=-0.26, 95% CI=-0.32, -0.20, p<0.001), and this same trend was seen for self-initiated and doctor-recommended treatments. Trends were driven by those with higher baseline cognitive performance—those with lower performance saw cognitive declines following sleep treatment. CONCLUSIONS In middle-aged and older adults with sleep disturbance, starting sleep treatment may slow cognitive decline. Future research should assess types, combinations, and timing of treatments most effective in improving cognitive health in later life.

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S403-S404
Author(s):  
Christopher N Kaufmann ◽  
Mark W Bondi ◽  
James D Murphy ◽  
Xin Tu ◽  
Alison A Moore

Abstract Sleep disturbances are associated with cognitive decline but it is not clear if initiation of sleep treatments mitigates decline. We used the 2006-2014 Health and Retirement Study. At each wave, participants were administered cognitive assessments and scores were summed (values=0-35; higher=better cognition). All participants also reported if, in the past two weeks, they had taken medications or used other treatments to improve sleep. Our sample (N=4,650) included individuals who at baseline were cognitively normal and untreated for sleep, and at any wave reported some sleep disturbance. We characterized cognitive performance over study period with comparisons before and after sleep treatment initiation. Between 2006-2014, participants exhibited declines in cognitive performance (B=-2.40; 95% CI=-2.73, -2.06; p<0.001) after controlling for confounders. Following sleep treatment, cognitive decline became less pronounced (interaction B=0.94; 95% CI=0.21, 1.67; p=0.013). Results suggest that in older adults with sleep disturbance, initiation of sleep treatment may slow cognitive decline.


2013 ◽  
Vol 68 (12) ◽  
pp. 1512-1517 ◽  
Author(s):  
Christopher N. Kaufmann ◽  
Sarah L. Canham ◽  
Ramin Mojtabai ◽  
Amber M. Gum ◽  
Natalie D. Dautovich ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. P450-P451
Author(s):  
Daniela A. Ayala ◽  
Christopher N. Kaufmann ◽  
Emily C. Edmonds ◽  
Mark W. Bondi

2021 ◽  
pp. 1-16
Author(s):  
Ziqi Wang ◽  
Yige Zhang ◽  
Li Dong ◽  
Zihao Zheng ◽  
Dayong Zhong ◽  
...  

Background: Given that there is no specific drug to treat Alzheimer’s disease, non-pharmacologic interventions in people with subjective cognitive decline (SCD) and amnestic mild cognitive impairment (aMCI) are one of the most important treatment strategies. Objective: To clarify the efficacy of blue-green (500 nm) light therapy on sleep, mood, and physiological parameters in patients with SCD and aMCI is an interesting avenue to explore. Methods: This is a monocentric, randomized, and controlled trial that will last for 4 weeks. We will recruit 150 individuals aged 45 years or older from memory clinics and divide them into 5 groups: SCD treatment (n = 30), SCD control (n = 30), aMCI treatment (n = 30), aMCI control (n = 30), and a group of healthy adult subjects (n = 30) as a normal control (NC). Results: The primary outcome is the change in subjective and objective cognitive performance between baseline and postintervention visits (4 weeks after baseline). Secondary outcomes include changes in performance assessing from baseline, postintervention to follow-up (3 months after the intervention), as well as sleep, mood, and physiological parameters (including blood, urine, electrophysiology, and neuroimaging biomarkers). Conclusion: This study aims to provide evidence of the impact of light therapy on subjective and objective cognitive performance in middle-aged and older adults with SCD or aMCI. In addition, we will identify possible neurophysiological mechanisms of action underlying light therapy. Overall, this trial will contribute to the establishment of light therapy in the prevention of Alzheimer’s disease.


2017 ◽  
Vol 71 (8) ◽  
pp. 750-757 ◽  
Author(s):  
Liming Dong ◽  
Jacqueline Agnew ◽  
Ramin Mojtabai ◽  
Pamela J Surkan ◽  
Adam P Spira

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Kimberly Hreha ◽  
Brian Downer ◽  
Joshua R Ehrlich ◽  
Giulio Taglialatela

Introduction: Nearly 800,000 people in the United States sustain a stroke each year. Up to 60% of stroke survivors have visual impairments and/or ocular deficits, which may negatively impact functional performance, quality of life, and increase the risk for depression. Poor vision has been associated with cognitive decline in older adults, but little is known if vision impairment is a risk factor for cognitive decline among older adults who have survived a stroke. The purpose of this study was to evaluate the association between vision impairment and cognitive decline among stroke survivors and compare the cognitive trajectories of stroke survivors with and without visual impairment. Methods: We used data from four waves (2010-2016) of the Health and Retirement Study to investigate the cognitive health of stroke survivors with and without visual impairment. Vision (excellent-very good [ref], good, fair-poor) and stroke diagnosis were self-reported. Cognition was measured using the Telephone Interview for Cognitive Status. Linear mixed effects regression was used to model the association between overall, near, and far vision and change in cognitive function, adjusting for confounders. Results: The final sample included 1,475 stroke survivors. A majority were female (55.6%) and white (66.3%) and the mean age was 71.0 (11.7). Fair-poor overall ( B =-1.30, p <0.01), near ( B =-1.53, p <0.001), and far ( B =-1.27, p <0.001) vision, as well as good near ( B =-0.82, p <0.001) and far ( B =-0.48, p <0.05) vision were associated with significantly lower baseline cognitive function compared to excellent-very good vision. The association between self-rated vision and cognition decline was not statistically significant. Conclusions: We found that people with worst vision had lower cognitive functioning but not greater cognitive decline than stroke survivors with excellent-to-very good vision. Further research should investigate if specific types of vision impairment potentiate the risk of cognitive impairment and dementia in stroke survivors.


Circulation ◽  
2020 ◽  
Vol 141 (Suppl_1) ◽  
Author(s):  
Claudia Szlejf ◽  
Claudia K Suemoto ◽  
Carolina Janovsky ◽  
Paulo A LOTUFO ◽  
Isabela M Bensenor

Introduction: The role of subtle thyroid alterations on cognitive decline is controversial. We aimed to investigate the association of thyrotropin (TSH) and free thyroxine (FT4) with baseline performance on cognitive tests and with cognitive decline in middle-aged and older adults without overt thyroid disease. Methods: This is a longitudinal analysis of the Brazilian Longitudinal Study of Adult Health baseline and second wave, after 4 years of follow-up. We included participants aged ≥ 55 years without over thyroid disease, prevalent stroke and use of drugs that could affect thyroid function and cognition. TSH and FT4 were assessed at baseline. Cognition was evaluated at baseline and at the second wave using delayed word recall test (DWR), semantic verbal fluency test (SVF), and trail making test version B (TMT). Baseline and longitudinal associations of TSH tertiles and FT4 tertiles with cognitive performance were investigated with generalized estimating equations, adjusted for sociodemographic characteristics, lifestyle, cardiovascular risk factors, and depression. Results: The baseline mean age of the 4675 participants was 62.4 ± 5.8 years, 52.3% women (2445 out of 4675). At baseline, TSH levels were not associated with cognitive performance in any test, although the highest FT4 tertile was associated with poorer performance on DWR (β = -0.087, 95% CI = -0.155; -0.019) and SVF (β = -0.076, 95%CI = -0.143; -0.010) after adjustment. Additionally, the lowest FT4 tertile was associated with poorer performance on SVF (β = -0.090, 95%CI = -0.152; -0.028). Cognitive performance did not change after 4 years of follow-up and there was no effect of time on the association of thyroid hormone levels with cognitive performance. Conclusion: At baseline, FT4 levels were associated with worse cognitive performance in a relatively young sample. Neither baseline FT4 nor TSH were associated with cognitive decline after 4 years.


2014 ◽  
Vol 30 (3) ◽  
pp. 284-291 ◽  
Author(s):  
Sarah L. Canham ◽  
Christopher N. Kaufmann ◽  
Pia M. Mauro ◽  
Ramin Mojtabai ◽  
Adam P. Spira

Sign in / Sign up

Export Citation Format

Share Document